Actinogen Medical Limited

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) earlier this week completed the final patient visit in its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial, putting the company on course to report top-line results in November. CFO Will Souter told Proactive that reaching the final patient visit represented “a major milestone in any clinical trial”, following an interim analysis earlier in the year and three meetings of the independent data monitoring committee.

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has completed the final patient visit in its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial, keeping topline results from the closely watched study on track for release in November. The final participant visit took place in the United States, marking completion of all patient visits in the 247-person trial of Actinogen's lead drug candidate Xanamem, also known as emestedastat.

4:30pm: Wall Street caps winning month Wall Street closed lower on Monday, but the major indexes still wrapped up a winning August as investors look ahead...

The price Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) is reported to be paying is the first thing analysts have flagged, and on the face of it $12.9 billion for...

UBS has said recent falls in bond yields and oil prices offer only temporary relief, with structural forces likely to keep long-term borrowing costs high,...